COVID-19 Disease
22
0
0
14
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 27/100
9.1%
2 terminated out of 22 trials
87.5%
+1.0% vs benchmark
14%
3 trials in Phase 3/4
43%
6 of 14 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 14 completed trials
Clinical Trials (22)
VEGF and sFlt-1 Levels in the Pathogenesis and Severity of COVID-19 Disease
Study of LAU-7b for the Treatment of Coronavirus Disease 2019 (COVID-19) Disease in Adults
ABNCoV2 Vaccine in Adult Subjects Previously Vaccinated for SARS-CoV-2
A Phase 1/2 Safety and Immunogenicity Trial of COVID-19 Vaccine COVIVAC (Phase 1)
Diet, Exercise, and Nutrition Challenges in Mexican Adults During COVID-19: A Study
Systematic Assessment of SARS-CoV-2 Neurotropic Capacity in Modestly and Critically Ill Patients, and Patients Who Died From COVID-19
ABNCoV2 Vaccine in SARS-CoV-2 (COVID-19) Seronegative and Seropositive Adult Subjects
A Retrospective Study of Neural Network Model to Dynamically Quantificate the Severity in COVID-19 Disease
A Novel Nomogram to Predict Severity of COVID-19
Safety, Immunogenicity, and Efficacy of INO-4800 for COVID-19 in Adults at High Risk of SARS-CoV-2 Exposure
A Study of LAM-002A for the Prevention of Progression of COVID-19
Epidemiologic Register on Diabetes and COVID-19 in Tunisia
A Clinical Study to Assess the Efficacy and Safety of Amizon® Max in the Treatment of Moderate Covid-19, Caused by the SARS-CoV-2 Virus
COVID-19 Disease and Coagulopathy: Assessment of Clotting Factor Levels in Patients With SARS-CoV-2 Infection
Outcomes of Covid-19 Protective Measures in Endoscopy
Efficacy, Immunogenicity and Safety of BBIBP-CorV Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection.
A Phase II Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Efficacy of Exosomes Overexpressing CD24 to Prevent Clinical Deterioration in Patients With Moderate or Severe COVID-19 Infection
Role of Lymphocyte Subsets and Laboratory Measurements in COVID-19 Disease
Back to the Traditional: Anti-COX Drugs Can Improve the Outcome of COVID-19 Patients Admitted to ICU
Gastrointestinal Symptoms in COVID-19